Clinical Advancements
Here we try and keep up to date on the treatments new advancements newly available or in the pipeline.
February 2026 - This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it's putting that claim to the test. After attracting global attention from researchers and billions of dollars from Big Pharma, Neomorph announced that it has begun its first clinical trial. The molecular glue aims to treat a form of kidney cancer.
January 2026 - A new state-of-the-art high-intensity focused ultrasound (HIFU) machine, the JC200 manufactured by Haifu Technology Ltd, has been installed at the Churchill Hospital, giving Oxford University Hospitals (OUH) patients access to the latest in this innovative technology.
January 2026 - The National Institute for Health and Care Excellence (NICE) has approved the combination of avelumab, an immunotherapy, plus axitinib, a tyrosine kinase inhibitor, for previously untreated patients with advanced favourable risk kidney cancer on the NHS in England and Wales. This brings the two countries in line with Scotland, which has allowed NHS access to the combination since 2020, ending the inequality in access within the UK.
September 2025 - Benmelstobart plus anlotinib improved progression-free survival compared with sunitinib among patients with previously untreated, advanced clear-cell renal cell carcinoma. These findings suggest the potential of benmelstobart plus anlotinib as a treatment option for this population.
August 2025 - 3D-printed kidney tumors show potential for more targeted treatment.
July 2025 - Cancer vaccines have always chased a moving target, every tutor is genetically unique. But what if we stop chasing specific mutations and start reprogramming the immune system itself?
13th June 2025, researchers at Johns Hopkins Medicine found that fragments of tumour DNA can appear in the bloodstream up to three years before a cancer diagnosis, offering a potentially revolutionary window for early detection and treatment.
This article from April 2025 explains how the subcutaneous formulation of nivolumab can be given as a 3–5-minute injection instead of the 30- or 60-minute intravenous (IV) infusion.
This article from March 2025, explains how a simple urine test could detect a recurrence of kidney cancer, halving post-op scans.
This article from February 2025 by Ojas Rajkumar and Professor Lennard Lee, covers the latest exciting vaccine developments in the UK.
​